New and revisited approaches to preserving the reperfused myocardium.
Authors:
Journal: Nature reviews. Cardiology
Publication Type: Journal Article
Date: 2017
DOI: NIHMS969246
ID: 28748958
Abstract
Early coronary artery reperfusion improves outcomes for patients with ST-segment elevation myocardial infarction (STEMI), but morbidity and mortality after STEMI remain unacceptably high. The primary deficits seen in these patients include inadequate pump function, owing to rapid infarction of muscle in the first few hours of treatment, and adverse remodelling of the heart in the months that follow. Given that attempts to further reduce myocardial infarct size beyond early reperfusion in clinical trials have so far been disappointing, effective therapies are still needed to protect the reperfused myocardium. In this Review, we discuss several approaches to preserving the reperfused heart, such as therapies that target the mechanisms involved in mitochondrial bioenergetics, pyroptosis, and autophagy, as well as treatments that harness the cardioprotective properties of inhaled anaesthetic agents. We also discuss potential therapies focused on correcting the no-reflow phenomenon and its effect on healing and adverse left ventricular remodelling.
Reference List
- Gerczuk PZ, Kloner RA. An update on cardioprotection: a review of the latest adjunctive therapies to limit myocardial infarction size in clinical trials. J Am Coll Cardiol. 2012;59:969–978.|||Hausenloy DJ, et al. Targeting reperfusion injury in patients with ST-segment elevation myocardial infarction: trials and tribulations. Eur Heart J. 2016;38:935–941.|||Menees DS, et al. Door-to-balloon time and mortality among patients undergoing primary PCI. N Engl J Med. 2013;369:901–909.|||Mozaffarian D, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322.|||Iliodromitis EK, et al. What is wrong with cardiac conditioning? We may shoot moving targets. J Cardiovasc Pharmacol Ther. 2015;20:357–369.|||Yang XM, et al. Platelet P2Y12 blockers confer direct postconditioning-like protection in reperfused rabbit hearts. J Cardiovasc Pharmacol Ther. 2013;18:251–262.|||Yang XM, et al. Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc Drugs Ther. 2013;27:109–115.|||Yang XM, Cui L, Alhammouri A, Downey JM, Cohen MV. Triple therapy greatly increases myocardial salvage during ischemia/reperfusion in the in situ rat heart. Cardiovasc Drugs Ther. 2013;27:403–412.|||Luz A, et al. Lack of benefit of ischemic postconditioning after routine thrombus aspiration during reperfusion: immediate and midterm results. J Cardiovasc Pharmacol Ther. 2015;20:523–531.|||Mentias A, et al. Ischemic postconditioning during primary percutaneous coronary intervention. Catheter Cardiovasc Interv. 2017 http://dx.doi.org/10.1002/ccd.26965.|||Elbadawi A, Ha LD, Abuzaid AS, Crimi G, Azzouz MS. Meta-analysis of randomized trials on remote ischemic conditioning during primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction. Am J Cardiol. 2017;119:832–838.|||Gao J, et al. The effects of remote ischemic conditioning in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: a meta-analysis. Minerva Med. 2017 http://dx.doi.org/10.23736/s0026-4806.17.04631-6.|||Le Page S, Bejan-Angoulvant T, Angoulvant D, Prunier F. Remote ischemic conditioning and cardioprotection: a systematic review and meta-analysis of randomized clinical trials. Bas Res Cardiol. 2015;110:11.|||Man C, Gong D, Zhou Y, Fan Y. Meta-analysis of remote ischemic conditioning in patients with acute myocardial infarction. Sci Rep. 2017;7:43529.|||Hale SL, Kloner RA. Myocardial temperature in acute myocardial infarction: protection with mild regional hypothermia. Am J Physiol. 1997;273:H220–227.|||Herring MJ, Dai W, Hale SL, Kloner RA. Rapid induction of hypothermia by the thermosuit system profoundly reduces infarct size and anatomic zone of no reflow following ischemia-reperfusion in rabbit and rat hearts. J Cardiovasc Pharmacol Ther. 2015;20:193–202.|||Pfeffer MA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med. 1992;327:669–677.|||Fisher SA, Doree C, Taggart DP, Mathur A, Martin-Rendon E. Cell therapy for heart disease: trial sequential analyses of two Cochrane reviews. Clin Pharmacol Ther. 2016;100:88–101.|||Zhu K, Li J, Wang Y, Lai H, Wang C. Nanoparticles-assisted stem cell therapy for ischemic heart disease. Stem Cells Int. 2016;2016:1384658.|||Tang J, et al. Therapeutic microparticles functionalized with biomimetic cardiac stem cell membranes and secretome. Nat Commun. 2017;8:13724.|||Gerczuk PZ, Kloner RA. Protecting the heart from ischemia: an update on ischemic and pharmacologic conditioning. Hosp Pract. 2011;39:35–43. 1995.|||Kloner RA, Dai W, Hale SL, Shi J. Approaches to improving cardiac structure and function during and after an acute myocardial infarction: acute and chronic phases. J Cardiovasc Pharmacol Ther. 2015;21:363–367.|||US National Library of Medicine. Transplantation of autologous derived mitochondria following ischemia. ClinicalTrialsgov. 2016 https://clinicaltrials.gov/ct2/show/NCT02851758.|||Brown DA, et al. Expert consensus document: mitochondrial function as a therapeutic target in heart failure. Nat Rev Cardiol. 2016;14:238–250.|||Brown DA, Sabbah HN, Shaikh SR. Mitochondrial inner membrane lipids and proteins as targets for decreasing cardiac ischemia/reperfusion injury. Pharmacol Ther. 2013;140:258–266.|||Murphy E, Steenbergen C. Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008;88:581–609.|||Walters AM, Porter GA, Jr, Brookes PS. Mitochondria as a drug target in ischemic heart disease and cardiomyopathy. Circ Res. 2012;111:1222–1236.|||Brown DA, O’Rourke B. Cardiac mitochondria and arrhythmias. Cardiovasc Res. 2010;88:241–249.|||Hausenloy DJ, Yellon DM. Targeting myocardial reperfusion injury—the search continues. N Engl J Med. 2015;373:1073–1075.|||Murphy E, Steenbergen C. Ion transport and energetics during cell death and protection. Physiol (Bethesda, Md ) 2008;23:115–123.|||Murphy MP. How mitochondria produce reactive oxygen species. Biochem J. 2009;417:1–13.|||Orr AL, et al. Inhibitors of ROS production by the ubiquinone-binding site of mitochondrial complex I identified by chemical screening. Free Radic Biol Med. 2013;65:1047–1059.|||Siu KL, Lotz C, Ping P, Cai H. Netrin-1 abrogates ischemia/reperfusion-induced cardiac mitochondrial dysfunction via nitric oxide-dependent attenuation of NOX4 activation and recoupling of NOS. J Mol Cell Cardiol. 2015;78:174–185.|||Kaludercic N, Carpi A, Menabo R, Di Lisa F, Paolocci N. Monoamine oxidases (MAO) in the pathogenesis of heart failure and ischemia/reperfusion injury. Biochim Biophys Acta. 2011;1813:1323–1332.|||Kaludercic N, Mialet-Perez J, Paolocci N, Parini A, Di Lisa F. Monoamine oxidases as sources of oxidants in the heart. J Mol Cell Cardiol. 2014;73:34–42.|||Alleman RJ, Katunga LA, Nelson MA, Brown DA, Anderson EJ. The “Goldilocks Zone” from a redox perspective — Adaptive vs. deleterious responses to oxidative stress in striated muscle. Frontiers Physiol. 2014;5:358.|||Frasier CR, et al. Redox-dependent increases in glutathione reductase and exercise preconditioning: role of NADPH oxidase and mitochondria. Cardiovasc Res. 2013;98:47–55.|||Nelson MJ, Harris MB, Boluyt MO, Hwang HS, Starnes JW. Effect of N-2- mercaptopropionyl glycine on exercise-induced cardiac adaptations. Am J Physiol Regul Integr Comp Physiol. 2011;300:R993–R1000.|||Pain T, et al. Opening of mitochondrial KATP channels triggers the preconditioned state by generating free radicals. Circ Res. 2000;87:460–466.|||Rosca MG, Tandler B, Hoppel CL. Mitochondria in cardiac hypertrophy and heart failure. J Mol Cell Cardiol. 2013;55:31–41.|||Song M, et al. Super-suppression of mitochondrial reactive oxygen species signaling impairs compensatory autophagy in primary mitophagic cardiomyopathy. Circ Res. 2014;115:348–353.|||Bolli R, et al. Direct evidence that oxygen-derived free radicals contribute to postischemic myocardial dysfunction in the intact dog. Proc Natl Acad Sci USA. 1989;86:4695–4699.|||Kloner RA, et al. Reduction of ischemia/reperfusion injury with bendavia, a mitochondria-targeting cytoprotective peptide. J Am Heart Assoc. 2012;1:e001644.|||Zweier JL. Measurement of superoxide-derived free radicals in the reperfused heart. Evidence for a free radical mechanism of reperfusion injury. J Biol Chem. 1988;263:1353–1357.|||Zweier JL, Flaherty JT, Weisfeldt ML. Direct measurement of free radical generation following reperfusion of ischemic myocardium. Proc Natl Acad Sci USA. 1987;84:1404–1407.|||Zweier JL, et al. Measurement and characterization of postischemic free radical generation in the isolated perfused heart. J Biol Chem. 1989;264:18890–18895.|||Chouchani ET, et al. Ischaemic accumulation of succinate controls reperfusion injury through mitochondrial ROS. Nature. 2014;515:431–435.|||Acin-Perez R, Fernandez-Silva P, Peleato ML, Perez-Martos A, Enriquez JA. Respiratory active mitochondrial supercomplexes. Mol Cell. 2008;32:529–539.|||Genova ML, Lenaz G. Functional role of mitochondrial respiratory supercomplexes. Biochim Biophys Acta. 2014;1837:427–443.|||Lapuente-Brun E, et al. Supercomplex assembly determines electron flux in the mitochondrial electron transport chain. Science. 2013;340:1567–1570.|||Schagger H. Respiratory chain supercomplexes of mitochondria and bacteria. Biochim Biophys Acta. 2002;1555:154–159.|||Jang S, et al. Elucidating mitochondrial electron transport chain supercomplexes in the heart during ischemia-reperfusion. Antioxid Redox Signal. 2016;27:57–69.|||Gomez LA, Monette JS, Chavez JD, Maier CS, Hagen TM. Supercomplexes of the mitochondrial electron transport chain decline in the aging rat heart. Arch Biochem Biophys. 2009;490:30–35.|||Rosca M, Minkler P, Hoppel CL. Cardiac mitochondria in heart failure: normal cardiolipin profile and increased threonine phosphorylation of complex IV. Biochim Biophys Acta. 2011;1807:1373–1382.|||Maranzana E, Barbero G, Falasca AI, Lenaz G, Genova ML. Mitochondrial respiratory supercomplex association limits production of reactive oxygen species from complex I. Antioxid Redox Signal. 2013;19:1469–1480.|||Escobales N, et al. Mitochondria-targeted ROS scavenger improves post-ischemic recovery of cardiac function and attenuates mitochondrial abnormalities in aged rats. J Mol Cell Cardiol. 2014;77:136–146.|||Ni R, et al. Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. Free Radic Biol Med. 2016;90:12–23.|||Eto M, Kajihara N, Morita S, Tominaga R. A novel electron paramagnetic resonance spin-probe technique demonstrates the relation between the production of hydroxyl radicals and ischemia-reperfusion injury. Eur J Cardiothorac Surg. 2011;39:465–470.|||Liu Y, et al. The alternative crosstalk between RAGE and nitrative thioredoxin inactivation during diabetic myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab. 2012;303:E841–E852.|||Pucheu S, Boucher F, Malfroy B, De Leiris J. Protective effect of the superoxide scavenger EUK8 against ultrastructural alterations induced by ischemia and reperfusion in isolated rat hearts. Nutrition. 1995;11:582–584.|||van Empel VP, et al. EUK-8, a superoxide dismutase and catalase mimetic, reduces cardiac oxidative stress and ameliorates pressure overload-induced heart failure in the harlequin mouse mutant. J Am Coll Cardiol. 2006;48:824–832.|||Xu Y, Liu B, Zweier JL, He G. Formation of hydrogen peroxide and reduction of peroxynitrite via dismutation of superoxide at reperfusion enhances myocardial blood flow and oxygen consumption in postischemic mouse heart. J Pharmacol Exp Ther. 2008;327:402–410.|||Nistri S, et al. A new low molecular weight, MnII-containing scavenger of superoxide anion protects cardiac muscle cells from hypoxia/reoxygenation injury. Free Radic Res. 2015;49:67–77.|||Bovo E, Lipsius SL, Zima AV. Reactive oxygen species contribute to the development of arrhythmogenic Ca2+ waves during beta-adrenergic receptor stimulation in rabbit cardiomyocytes. J Physiol. 2012;590:3291–3304.|||Flaherty JT, et al. Recombinant human superoxide dismutase (h-SOD) fails to improve recovery of ventricular function in patients undergoing coronary angioplasty for acute myocardial infarction. Circulation. 1994;89:1982–1991.|||Tsujita K, et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction. Am J Cardiol. 2004;94:481–484.|||Maulik N, et al. Dietary coenzyme Q(10) supplement renders swine hearts resistant to ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2000;278:H1084–H1090.|||Whitman GJ, et al. The mechanisms of coenzyme Q10 as therapy for myocardial ischemia reperfusion injury. Mol Aspects Med. 1997;18(Suppl):S195–S203.|||Mortensen SA, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail. 2014;2:641–649.|||Adlam VJ, et al. Targeting an antioxidant to mitochondria decreases cardiac ischemia-reperfusion injury. FASEB J. 2005;19:1088–1095.|||Skulachev VP, et al. An attempt to prevent senescence: a mitochondrial approach. Biochim Biophys Acta. 2009;1787:437–461.|||Lyamzaev KG, et al. Novel mitochondria-targeted antioxidants: plastoquinone conjugated with cationic plant alkaloids berberine and palmatine. Pharm Res. 2011;28:2883–2895.|||Lesnefsky EJ, et al. Blockade of electron transport during ischemia protects cardiac mitochondria. J Biol Chem. 2004;279:47961–47967.|||Bridges HR, Jones AJ, Pollak MN, Hirst J. Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J. 2014;462:475–487.|||Chen Q, Camara AK, Stowe DF, Hoppel CL, Lesnefsky EJ. Modulation of electron transport protects cardiac mitochondria and decreases myocardial injury during ischemia and reperfusion. Am J Physiol Cell Physiol. 2007;292:C137–C147.|||Yin M, et al. Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am J Physiol Heart Circ Physiol. 2011;301:H459–H468.|||Valls-Lacalle L, et al. Succinate dehydrogenase inhibition with malonate during reperfusion reduces infarct size by preventing mitochondrial permeability transition. Cardiovasc Res. 2016;109:374–384.|||Wojtovich AP, Brookes PS. The endogenous mitochondrial complex II inhibitor malonate regulates mitochondrial ATP-sensitive potassium channels: implications for ischemic preconditioning. Biochim Biophys Acta. 2008;1777:882–889.|||Chouchani ET, et al. Identification of S-nitrosated mitochondrial proteins by S-nitrosothiol difference in gel electrophoresis (SNO-DIGE): implications for the regulation of mitochondrial function by reversible S-nitrosation. Biochem J. 2010;430:49–59.|||Chouchani ET, et al. Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I. Nat Med. 2013;19:753–759.|||Methner C, et al. Mitochondria selective S-nitrosation by mitochondria-targeted S-nitrosothiol protects against post-infarct heart failure in mouse hearts. Eur J Heart Fail. 2014;16:712–717.|||Nadtochiy SM, Burwell LS, Brookes PS. Cardioprotection and mitochondrial S-nitrosation: effects of S-nitroso-2-mercaptopropionyl glycine (SNO-MPG) in cardiac ischemia-reperfusion injury. J Mol Cell Cardiol. 2007;42:812–825.|||Prime TA, et al. A mitochondria-targeted S-nitrosothiol modulates respiration, nitrosates thiols, and protects against ischemia-reperfusion injury. Proc Natl Acad Sci USA. 2009;106:10764–10769.|||Porter GA, Urciuoli WR, Brookes PS, Nadtochiy SM. SIRT3 deficiency exacerbates ischemia-reperfusion injury: implication for aged hearts. Am J Physiol Heart Circ Physiol. 2014;306:H1602–H1609.|||Dassanayaka S, Jones SP. O-GlcNAc and the cardiovascular system. Pharmacol Ther. 2014;142:62–71.|||Boylston JA, et al. Characterization of the cardiac succinylome and its role in ischemia-reperfusion injury. J Mol Cell Cardiol. 2015;88:73–81.|||Akhmedov A, et al. Genetic deletion of the adaptor protein p66Shc increases susceptibility to short-term ischaemic myocardial injury via intracellular salvage pathways. Eur Heart J. 2015;36:516–526.|||Carpi A, et al. The cardioprotective effects elicited by p66(Shc) ablation demonstrate the crucial role of mitochondrial ROS formation in ischemia/reperfusion injury. Biochim Biophys Acta. 2009;1787:774–780.|||Heusch G. Mitochondria at the heart of cardiovascular protection: p66shc-friend or foe? Eur Heart J. 2015;36:469–471.|||Akar FG, Aon MA, Tomaselli GF, O’Rourke B. The mitochondrial origin of postischemic arrhythmias. J Clin Invest. 2005;115:3527–3535.|||Alleman RJ, et al. Exercise-induced protection against reperfusion arrhythmia involves stabilization of mitochondrial energetics. Am J Physiol Heart Circ Physiol. 2016;310:H1360–H1370.|||Matsumoto-Ida M, Akao M, Takeda T, Kato M, Kita T. Real-time 2-photon imaging of mitochondrial function in perfused rat hearts subjected to ischemia/reperfusion. Circulation. 2006;114:1497–1503.|||Slodzinski MK, Aon MA, O’Rourke B. Glutathione oxidation as a trigger of mitochondrial depolarization and oscillation in intact hearts. J Mol Cell Cardiol. 2008;45:650–660.|||Aon MA, Cortassa S, O’Rourke B. Redox-optimized ROS balance: a unifying hypothesis. Biochim Biophys Acta. 2010;1797:865–877.|||Brand MD. Uncoupling to survive? The role of mitochondrial inefficiency in ageing. Exp Gerontol. 2000;35:811–820.|||Smith BK, et al. Salsalate (salicylate) uncouples mitochondria, improves glucose homeostasis, and reduces liver lipids independent of AMPK-β1. Diabetes. 2016;65:3352–3361.|||Quarrie R, et al. Mitochondrial uncoupling does not decrease reactive oxygen species production after ischemia-reperfusion. Am J Physiol Heart Circ Physiol. 2014;307:H996–H1004.|||Brennan JP, et al. Mitochondrial uncoupling, with low concentration FCCP, induces ROS-dependent cardioprotection independent of KATP channel activation. Cardiovasc Res. 2006;72:313–321.|||Nickel AG, et al. Reversal of mitochondrial transhydrogenase causes oxidative stress in heart failure. Cell Metab. 2015;22:472–484.|||O’Rourke B. Metabolism: beyond the power of mitochondria. Nat Rev Cardiol. 2016;13:386–388.|||Ioroi T, et al. Serofendic acid protects against myocardial ischemia-reperfusion injury in rats. J Pharmacol Sci. 2014;126:274–280.|||Brown DA, et al. Cardiac arrhythmias induced by glutathione oxidation can be inhibited by preventing mitochondrial depolarization. J Mol Cell Cardiol. 2010;48:673–679.|||Solhjoo S, O’Rourke B. Mitochondrial instability during regional ischemia-reperfusion underlies arrhythmias in monolayers of cardiomyocytes. J Mol Cell Cardiol. 2015;78:90–99.|||Zamzami N, et al. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med. 1995;181:1661–1672.|||Tang HL, et al. Cell survival, DNA damage, and oncogenic transformation after a transient and reversible apoptotic response. Mol Biol Cell. 2012;23:2240–2252.|||Ding AX, et al. CasExpress reveals widespread and diverse patterns of cell survival of caspase-3 activation during development in vivo. eLife. 2016;5:e10936.|||Alam MR, Baetz D, Ovize M. Cyclophilin D and myocardial ischemia-reperfusion injury: a fresh perspective. J Mol Cell Cardiol. 2015;78:80–89.|||Baines CP. The mitochondrial permeability transition pore and ischemia-reperfusion injury. Bas Res Cardiol. 2009;104:181–188.|||Bernardi P, Di Lisa F. The mitochondrial permeability transition pore: molecular nature and role as a target in cardioprotection. J Mol Cell Cardiol. 2015;78:100–106.|||Ong SB, Samangouei P, Kalkhoran SB, Hausenloy DJ. The mitochondrial permeability transition pore and its role in myocardial ischemia reperfusion injury. J Mol Cell Cardiol. 2015;78:23–34.|||Hausenloy DJ, Yellon DM, Mani-Babu S, Duchen MR. Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol. 2004;287:H841–H849.|||Lu X, Kwong JQ, Molkentin JD, Bers DM. Individual cardiac mitochondria undergo rare transient permeability transition pore openings. Circ Res. 2016;118:834–841.|||Carraro M, et al. Channel formation by yeast F-ATP synthase and the role of dimerization in the mitochondrial permeability transition. J Biol Chem. 2014;289:15980–15985.|||Giorgio V, et al. Dimers of mitochondrial ATP synthase form the permeability transition pore. Proc Natl Acad Sci USA. 2013;110:5887–5892.|||Mewton N, et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol. 2010;55:1200–1205.|||Piot C, et al. Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med. 2008;359:473–481.|||Cung TT, et al. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. N Engl J Med. 2015;373:1021–1031.|||Atar D, et al. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. Eur Heart J. 2015;36:112–119.|||Bell RM, et al. 9th Hatter Biannual Meeting: position document on ischaemia/reperfusion injury, conditioning and the ten commandments of cardioprotection. Bas Res Cardiol. 2016;111:41.|||Calmettes G, et al. Hexokinases and cardioprotection. J Mol Cell Cardiol. 2015;78:107–115.|||Halestrap AP, Pereira GC, Pasdois P. The role of hexokinase in cardioprotection - mechanism and potential for translation. Br J Pharmacol. 2015;172:2085–2100.|||Nederlof R, Eerbeek O, Hollmann MW, Southworth R, Zuurbier CJ. Targeting hexokinase II to mitochondria to modulate energy metabolism and reduce ischaemia-reperfusion injury in heart. Br J Pharmacol. 2014;171:2067–2079.|||Dube H, et al. A mitochondrial-targeted cyclosporin A with high binding affinity for cyclophilin D yields improved cytoprotection of cardiomyocytes. Biochem J. 2012;441:901–907.|||Cowan DB, et al. Intracoronary delivery of mitochondria to the ischemic heart for cardioprotection. PLoS ONE. 2016;11:e0160889.|||Kaza AK, et al. Myocardial rescue with autologous mitochondrial transplantation in a porcine model of ischemia/reperfusion. J Thorac Cardiovasc Surg. 2017;153:934–943.|||Masuzawa A, et al. Transplantation of autologously derived mitochondria protects the heart from ischemia-reperfusion injury. Am J Physiol Heart Circ Physiol. 2013;304:H966–H982.|||Brown DA, et al. Reduction of early reperfusion injury with the mitochondria-targeting peptide Bendavia. J Cardiovasc Pharmacol Ther. 2013;153:934–943.|||Dai W, et al. Cardioprotective effects of mitochondria-targeted peptide SBT-20 in two different models of rat ischemia/reperfusion. Cardiovasc Drugs Ther. 2016;30:559–566.|||Shi J, et al. Bendavia restores mitochondrial energy metabolism gene expression and suppresses cardiac fibrosis in the border zone of the infarcted heart. Life Sci. 2015;141:170–178.|||Zhao K, et al. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem. 2004;279:34682–34690.|||Tano JY, Gollasch M. Calcium-activated potassium channels in ischemia reperfusion: a brief update. Front Physiol. 2014;5:381.|||Foster DB, et al. Mitochondrial ROMK channel is a molecular component of mitoKATP. Circ Res. 2012;111:446–454.|||Foster MN, Coetzee WA. KATP channels in the cardiovascular system. Physiol Rev. 2016;96:177–252.|||Lefer DJ, Nichols CG, Coetzee WA. Sulfonylurea receptor 1 subunits of ATP-sensitive potassium channels and myocardial ischemia/reperfusion injury. Trends Cardiovasc Med. 2009;19:61–67.|||West AP, et al. Mitochondrial DNA stress primes the antiviral innate immune response. Nature. 2015;520:553–557.|||Yang XM, et al. Mitochondrially targeted Endonuclease III has a powerful anti-infarct effect in an in vivo rat model of myocardial ischemia/reperfusion. Bas Res Cardiol. 2015;110:3.|||Skulachev MV, et al. Mitochondrial-targeted plastoquinone derivatives. Effect on senescence and acute age-related pathologies. Curr Drug Targets. 2011;12:800–826.|||Smith RA, Hartley RC, Cocheme HM, Murphy MP. Mitochondrial pharmacology. Trends Pharmacol Sci. 2012;33:341–352.|||Smith RA, Hartley RC, Murphy MP. Mitochondria-targeted small molecule therapeutics and probes. Antioxid Redox Signal. 2011;15:3021–3038.|||Chernyak BV, et al. Novel mitochondria-targeted compounds composed of natural constituents: conjugates of plant alkaloids berberine and palmatine with plastoquinone. Biochem Biokhimiia. 2012;77:983–995.|||Pustovidko AV, et al. Derivatives of the cationic plant alkaloids berberine and palmatine amplify protonophorous activity of fatty acids in model membranes and mitochondria. Mitochondrion. 2013;13:520–525.|||Yousif LF, Stewart KM, Horton KL, Kelley SO. Mitochondria-penetrating peptides: sequence effects and model cargo transport. Chembiochem. 2009;10:2081–2088.|||Horton KL, Pereira MP, Stewart KM, Fonseca SB, Kelley SO. Tuning the activity of mitochondria-penetrating peptides for delivery or disruption. Chembiochem. 2012;13:476–485.|||Horton KL, Stewart KM, Fonseca SB, Guo Q, Kelley SO. Mitochondria-penetrating peptides. Chem Biol. 2008;15:375–382.|||Szeto HH, Schiller PW. Novel therapies targeting inner mitochondrial membrane—from discovery to clinical development. Pharm Res. 2011;28:2669–2679.|||Ikeda G, et al. Nanoparticle-mediated targeting of cyclosporine A enhances cardioprotection against ischemia-reperfusion injury through inhibition of mitochondrial permeability transition pore opening. Sci Rep. 2016;6:20467.|||Ishikita A, et al. Nanoparticle-mediated delivery of mitochondrial division inhibitor 1 to the myocardium protects the heart from ischemia-reperfusion injury through inhibition of mitochondria outer membrane permeabilization: a new therapeutic modality for acute myocardial infarction. J Am Heart Assoc. 2016;5:e003872.|||Guerrero-Beltran CE, et al. Silica nanoparticles induce cardiotoxicity interfering with energetic status and Ca2+ handling in adult rat cardiomyocytes. Am J Physiol Heart Circ Physiol. 2017;312:H645–H661.|||Thompson LC, et al. Pulmonary instillation of multi-walled carbon nanotubes promotes coronary vasoconstriction and exacerbates injury in isolated hearts. Nanotoxicology. 2014;8:38–49.|||Cope DK, Impastato WK, Cohen MV, Downey JM. Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology. 1997;86:699–709.|||De Hert SG, et al. Sevoflurane but not propofol preserves myocardial function in coronary surgery patients. Anesthesiology. 2002;97:42–49.|||Mellidis K, et al. Activation of prosurvival signaling pathways during the memory phase of volatile anesthetic preconditioning in human myocardium: a pilot study. Mol Cell Biochem. 2014;388:195–201.|||Riess ML, Stowe DF, Warltier DC. Cardiac pharmacological preconditioning with volatile anesthetics: from bench to bedside? Am J Physiol Heart Circ Physiol. 2004;286:H1603–H1607.|||Lang XE, et al. Isoflurane preconditioning confers cardioprotection by activation of ALDH2. PLoS ONE. 2013;8:e52469.|||Tampo A, Hogan CS, Sedlic F, Bosnjak ZJ, Kwok WM. Accelerated inactivation of cardiac L-type calcium channels triggered by anaesthetic-induced preconditioning. Br J Pharmacol. 2009;156:432–443.|||Amour J, et al. Role of heat shock protein 90 and endothelial nitric oxide synthase during early anesthetic and ischemic preconditioning. Anesthesiology. 2009;110:317–325.|||Hieber S, Huhn R, Hollmann MW, Weber NC, Preckel B. Hypoxia-inducible factor 1 and related gene products in anaesthetic-induced preconditioning. Eur J Anaesthesiol. 2009;26:201–206.|||Julier K, et al. Preconditioning by sevoflurane decreases biochemical markers for myocardial and renal dysfunction in coronary artery bypass graft surgery: a double-blinded, placebo-controlled, multicenter study. Anesthesiology. 2003;98:1315–1327.|||Lucchinetti E, et al. Remote ischemic preconditioning applied during isoflurane inhalation provides no benefit to the myocardium of patients undergoing on-pump coronary artery bypass graft surgery: lack of synergy or evidence of antagonism in cardioprotection? Anesthesiology. 2012;116:296–310.|||Suleiman MS, Zacharowski K, Angelini GD. Inflammatory response and cardioprotection during open-heart surgery: the importance of anaesthetics. Br J Pharmacol. 2008;153:21–33.|||Nguyen LT, et al. Attenuation of isoflurane-induced preconditioning and reactive oxygen species production in the senescent rat heart. Anesthesia Analgesia. 2008;107:776–782.|||Kehl F, et al. Hyperglycemia prevents isoflurane-induced preconditioning against myocardial infarction. Anesthesiology. 2002;96:183–188.|||Canfield SG, et al. Marked hyperglycemia attenuates anesthetic preconditioning in human-induced pluripotent stem cell-derived cardiomyocytes. Anesthesiology. 2012;117:735–744.|||Saxena A, Russo I, Frangogiannis NG. Inflammation as a therapeutic target in myocardial infarction: learning from past failures to meet future challenges. Transl Res. 2016;167:152–166.|||Takahashi M. NLRP3 inflammasome as a novel player in myocardial infarction. Int Heart J. 2014;55:101–105.|||Franchi L, Munoz-Planillo R, Nunez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012;13:325–332.|||Aglietti RA, et al. GsdmD p30 elicited by caspase-11 during pyroptosis forms pores in membranes. Proc Natl Acad Sci USA. 2016;113:7858–7863.|||Liu X, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature. 2016;535:153–158.|||Arnoult D, Soares F, Tattoli I, Girardin SE. Mitochondria in innate immunity. EMBO Rep. 2011;12:901–910.|||Garcia N, Chavez E. Mitochondrial DNA fragments released through the permeability transition pore correspond to specific gene size. Life Sci. 2007;81:1160–1166.|||Man SM, Karki R, Kanneganti TD. DNA-sensing inflammasomes: regulation of bacterial host defense and the gut microbiota. Pathog Dis. 2016;74:ftw028.|||Zhang Q, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464:104–107.|||Simmons JD, et al. Mitochondrial DNA damage associated molecular patterns in ventilator-associated pneumonia: prevention and reversal by intratracheal DNase I. J Trauma Acute Care Surg. 2017;82:120–125.|||Bliksoen M, et al. Extracellular mtDNA activates NF-κB via toll-like receptor 9 and induces cell death in cardiomyocytes. Bas Res Cardiol. 2016;111:42.|||Kawaguchi M, et al. Inflammasome activation of cardiac fibroblasts is essential for myocardial ischemia/reperfusion injury. Circulation. 2011;123:594–604.|||Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA. Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1β. Proc Natl Acad Sci USA. 2001;98:2871–2876.|||Jong WM, et al. Nlrp3 plays no role in acute cardiac infarction due to low cardiac expression. Int J Cardiol. 2014;177:41–43.|||Sandanger O, et al. NLRP3 inflammasome activation during myocardial ischemia reperfusion is cardioprotective. Biochem Biophys Res Commun. 2016;469:1012–1020.|||Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140:821–832.|||Marchetti C, et al. A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse. J Cardiovasc Pharmacol. 2014;63:316–322.|||Mastrocola R, et al. Pharmacological inhibition of NLRP3 inflammasome attenuates myocardial ischemia/reperfusion injury by activation of RISK and mitochondrial pathways. Oxid Med Cell Longev. 2016;2016:5271251.|||van Hout GP, et al. The selective NLRP3- inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. Eur Heart J. 2016;38:828–836.|||Holly TA, et al. Caspase inhibition reduces myocyte cell death induced by myocardial ischemia and reperfusion in vivo. J Mol Cell Cardiol. 1999;31:1709–1715.|||Syed FM, et al. Proapoptotic effects of caspase-1/interleukin-converting enzyme dominate in myocardial ischemia. Circ Res. 2005;96:1103–1109.|||Koshinuma S, Miyamae M, Kaneda K, Kotani J, Figueredo VM. Combination of necroptosis and apoptosis inhibition enhances cardioprotection against myocardial ischemia-reperfusion injury. J Anesthesia. 2014;28:235–241.|||Mocanu MM, Baxter GF, Yellon DM. Caspase inhibition and limitation of myocardial infarct size: protection against lethal reperfusion injury. Br J Pharmacol. 2000;130:197–200.|||Duprez L, Wirawan E, Vanden Berghe T, Vandenabeele P. Major cell death pathways at a glance. Microbes Infection. 2009;11:1050–1062.|||Shimada K, et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity. 2012;36:401–414.|||Shao W, Yeretssian G, Doiron K, Hussain SN, Saleh M. The caspase-1 digestome identifies the glycolysis pathway as a target during infection and septic shock. J Biol Chem. 2007;282:36321–36329.|||Yang X-M, et al. The highly selective caspase-1 inhibitor VX-765 provides additive protection against myocardial infarction in rat hearts when combined with a platelet inhibitor. J Cardiovasc Pharmacol Ther. 2017 http://dx.doi.org/10.1177/1074248417702890.|||Yu J, et al. Inflammasome activation leads to Caspase-1-dependent mitochondrial damage and block of mitophagy. Proc Natl Acad Sci USA. 2014;111:15514–15519.|||Oka T, et al. Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure. Nature. 2012;485:251–255.|||Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. Circulation. 1986;74:1124–1136.|||Huang C, et al. Autophagy and protein kinase C are required for cardioprotection by sulfaphenazole. Am J Physiol Heart Circ Physiol. 2010;298:H570–H579.|||Yitzhaki S, et al. Autophagy is required for preconditioning by the adenosine A1 receptor-selective agonist CCPA. Bas Res Cardiol. 2009;104:157–167.|||Wang LQ, Cheng XS, Huang CH, Huang B, Liang Q. Rapamycin protects cardiomyocytes against anoxia/reoxygenation injury by inducing autophagy through the PI3k/Akt pathway. J Huazhong Univ Sci Technolog Med Sci. 2015;35:10–15.|||Wu X, et al. Induction of autophagy contributes to the myocardial protection of valsartan against ischemiareperfusion injury. Mol Med Rep. 2013;8:1824–1830.|||Gurusamy N, et al. Cardioprotection by resveratrol: a novel mechanism via autophagy involving the mTORC2 pathway. Cardiovasc Res. 2010;86:103–112.|||Xie M, et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy. Circulation. 2014;129:1139–1151.|||Rohailla S, et al. Acute, delayed and chronic remote ischemic conditioning is associated with downregulation of mTOR and enhanced autophagy signaling. PLoS ONE. 2014;9:e111291.|||Gurusamy N, Lekli I, Gherghiceanu M, Popescu LM, Das DK. BAG-1 induces autophagy for cardiac cell survival. Autophagy. 2009;5:120–121.|||Park HK, et al. Autophagy is involved in the ischemic preconditioning. Neurosci Lett. 2009;451:16–19.|||Yan L, Sadoshima J, Vatner DE, Vatner SF. Autophagy in ischemic preconditioning and hibernating myocardium. Autophagy. 2009;5:709–712.|||Huang C, et al. Autophagy induced by ischemic preconditioning is essential for cardioprotection. J Cardiovasc Transl Res. 2010;3:365–373.|||Huang C, et al. Preconditioning involves selective mitophagy mediated by Parkin and p62/SQSTM1. PLoS ONE. 2011;6:e20975.|||Andres AM, et al. Mitophagy is required for acute cardioprotection by simvastatin. Antioxid Redox Signal. 2014;21:1960–1973.|||Matsui Y, et al. Distinct roles of autophagy in the heart during ischemia and reperfusion: roles of AMP-activated protein kinase and Beclin 1 in mediating autophagy. Circ Res. 2007;100:914–922.|||Schiattarella GG, Hill JA. Therapeutic targeting of autophagy in cardiovascular disease. J Mol Cell Cardiol. 2016;95:86–93.|||Bhuiyan MS, et al. Enhanced autophagy ameliorates cardiac proteinopathy. J Clin Invest. 2013;123:5284–5297.|||Delbridge LM, Mellor KM, Taylor DJ, Gottlieb RA. Myocardial autophagic energy stress responses—macroautophagy, mitophagy, and glycophagy. Am J Physiol Heart Circ Physiol. 2015;308:H1194–H1204.|||Gottlieb RA, Andres AM, Sin J, Taylor DPJ. Untangling autophagy measurements: all fluxed up. Circ Res. 2015;116:504–514.|||Han Z, et al. Autophagy is involved in the cardioprotection effect of remote limb ischemic postconditioning on myocardial ischemia/reperfusion injury in normal mice, but not diabetic mice. PLoS ONE. 2014;9:e86838.|||Ke J, Yao B, Li T, Cui S, Ding H. A2 adenosine receptor-mediated cardioprotection against reperfusion injury in rat hearts is associated with autophagy downregulation. J Cardiovasc Pharmacol. 2015;66:25–34.|||Su J, Zhang T, Wang K, Zhu T, Li X. Autophagy activation contributes to the neuroprotection of remote ischemic perconditioning against focal cerebral ischemia in rats. Neurochem Res. 2014;39:2068–2077.|||Zhang YL, et al. Restoration of autophagic flux in myocardial tissues is required for cardioprotection of sevoflurane postconditioning in rats. Acta Pharmacol Sin. 2014;35:758–769.|||Koike M, et al. Inhibition of autophagy prevents hippocampal pyramidal neuron death after hypoxic-ischemic injury. Am J Pathol. 2008;172:454–469.|||Xing S, et al. Beclin 1 knockdown inhibits autophagic activation and prevents the secondary neurodegenerative damage in the ipsilateral thalamus following focal cerebral infarction. Autophagy. 2012;8:63–76.|||Liu Y, et al. Autosis is a Na+, K+-ATPase-regulated form of cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. Proc Natl Acad Sci USA. 2013;110:20364–20371.|||Elgendy M, Sheridan C, Brumatti G, Martin SJ. Oncogenic Ras-induced expression of Noxa and Beclin-1 promotes autophagic cell death and limits clonogenic survival. Mol Cell. 2011;42:23–35.|||Rothermel BA, Hill JA. Autophagy in load-induced heart disease. Circ Res. 2008;103:1363–1369.|||Wang Q, Ren J. mTOR-Independent autophagy inducer trehalose rescues against insulin resistance-induced myocardial contractile anomalies: Role of p38 MAPK and Foxo1. Pharmacol Res. 2016;111:357–373.|||Jang SY, Kang HT, Hwang ES. Nicotinamide-induced mitophagy: event mediated by high NAD+/NADH ratio and SIRT1 protein activation. J Biol Chem. 2012;287:19304–19314.|||Lee IH, et al. A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy. Proc Natl Acad Sci USA. 2008;105:3374–3379.|||Liu G, et al. Loss of NAD-dependent protein deacetylase sirtuin-2 alters mitochondrial protein acetylation and dysregulates mitophagy. Antioxid Redox Signal. 2016;26:849–863.|||Bo L, et al. Autophagic program is regulated by miR-325. Cell Death Differ. 2014;21:967–977.|||Chen Q, Zhou Y, Richards AM, Wang P. Up-regulation of miRNA-221 inhibits hypoxia/reoxygenation-induced autophagy through the DDIT4/mTORC1 and Tp53inp1/p62 pathways. Biochem Biophys Res Commun. 2016;474:168–174.|||Gottlieb RA, Pourpirali S. Lost in translation: miRNAs and mRNAs in ischemic preconditioning and ischemia/reperfusion injury. J Mol Cell Cardiol. 2016;95:70–77.|||Gupta SK, Thum T. Non-coding RNAs as orchestrators of autophagic processes. J Mol Cell Cardiol. 2016;95:26–30.|||Higashi K, et al. MicroRNA-145 repairs infarcted myocardium by accelerating cardiomyocyte autophagy. Am J Physiol Heart Circ Physiol. 2015;309:H1813–1826.|||Huang J, Huang C, Luo Y, Liu S, Chen X. Role of MiR.-30a in cardiomyocyte autophagy induced by Angiotensin, II. J Renin Angiotensin Aldosterone Syst. 2015;16:1–5.|||Li D, et al. Salvianolic acid B induced upregulation of miR-30a protects cardiac myocytes from ischemia/reperfusion injury. BMC Complement Alternative Med. 2016;16:336.|||Li G, et al. miR-22 regulates starvation-induced autophagy and apoptosis in cardiomyocytes by targeting p38α. Biochem Biophys Res Commun. 2016;478:1165–1172.|||Li X, et al. Inhibition of microRNA-497 ameliorates anoxia/reoxygenation injury in cardiomyocytes by suppressing cell apoptosis and enhancing autophagy. Oncotarget. 2015;6:18829–18844.|||Nandi SS, et al. Induction of autophagy markers is associated with attenuation of miR-133a in diabetic heart failure patients undergoing mechanical unloading. Am J Transl Res. 2015;7:683–696.|||Su M, et al. Cardiac-specific overexpression of miR-222 induces heart failure and inhibits autophagy in mice. Cell Physiol Biochem. 2016;39:1503–1511.|||Su M, et al. MicroRNA-221 inhibits autophagy and promotes heart failure by modulating the p27/CDK2/mTOR axis. Cell Death Differ. 2015;22:986–999.|||Wang K, et al. APF lncRNA regulates autophagy and myocardial infarction by targeting miR-188-3p. Nat Commun. 2015;6:6779.|||Wu D, Jiang H, Chen S, Zhang H. Inhibition of microRNA-101 attenuates hypoxia/reoxygenationinduced apoptosis through induction of autophagy in H9c2 cardiomyocytes. Mol Med Rep. 2015;11:3988–3994.|||Yang Y, et al. Exosomal transfer of miR-30a between cardiomyocytes regulates autophagy after hypoxia. J Mol Med (Berlin, Germany) 2016;94:711–724.|||Zou Y, Liu W, Zhang J, Xiang D. miR-153 regulates apoptosis and autophagy of cardiomyocytes by targeting Mcl-1. Mol Med Rep. 2016;14:1033–1039.|||Li J, et al. MicroRNA-144 is a circulating effector of remote ischemic preconditioning. Bas Res Cardiol. 2014;109:423.|||Ma X, et al. Impaired autophagosome clearance contributes to cardiomyocyte death in ischemia-reperfusion injury. Circulation. 2012;125:3170–3181.|||Shirakabe A, et al. Drp1-dependent mitochondrial autophagy plays a protective role against pressure overload-induced mitochondrial dysfunction and heart failure. Circulation. 2016;133:1249–1263.|||Foyil SA, et al. BNIP3-induced aurophagy plays a protective role against pressure overload-induced mitochondrial dysfunction and heart failure. J Cardiac Fail. 2010;16:S35.|||Cao DJ, et al. Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy. Proc Natl Acad Sci USA. 2011;108:4123–4128.|||Huang J, et al. LC3B, a protein that serves as an autophagic marker, modulates angiotensin ii-induced myocardial hypertrophy. J Cardiovasc Pharmacol. 2015;66:576–583.|||Zhou L, Ma B, Han X. The role of autophagy in angiotensin II-induced pathological cardiac hypertrophy. J Mol Endocrinol. 2016;57:R143–R152.|||Ikeda Y, et al. Endogenous Drp1 mediates mitochondrial autophagy and protects the heart against energy stress. Circ Res. 2015;116:264–278.|||Shen C, et al. Acetaldehyde dehydrogenase 2 (ALDH2) deficiency exacerbates pressure overload-induced cardiac dysfunction by inhibiting Beclin-1 dependent autophagy pathway. Biochim Biophys Acta. 2015;1852:310–318.|||Ahmet I, Wan R, Mattson MP, Lakatta EG, Talan M. Cardioprotection by intermittent fasting in rats. Circulation. 2005;112:3115–3121.|||Godar RJ, et al. Repetitive stimulation of autophagy-lysosome machinery by intermittent fasting preconditions the myocardium to ischemia-reperfusion injury. Autophagy. 2015;11:1537–1560.|||Hatori M, et al. Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab. 2012;15:848–860.|||Hsu HC, Chen CY, Lee BC, Chen MF. High-fat diet induces cardiomyocyte apoptosis via the inhibition of autophagy. Eur J Nutr. 2016;55:2245–2254.|||Hsu HC, et al. Time-dependent cellular response in the liver and heart in a dietary-induced obese mouse model: the potential role of ER stress and autophagy. Eur J Nutr. 2016;55:2031–2043.|||Andres AM, et al. Discordant signaling and autophagy response to fasting in hearts of obese mice: Implications for ischemia tolerance. Am J Physiol Heart Circ Physiol. 2016;311:H219–H228.|||Powers SK, Quindry JC, Kavazis AN. Exercise-induced cardioprotection against myocardial ischemia-reperfusion injury. Free Radic Biol Med. 2008;44:193–201.|||Tam BT, et al. Autophagic adaptations to long-term habitual exercise in cardiac muscle. Int J Sports Med. 2015;36:526–534.|||Iyer SS, et al. Mitochondrial cardiolipin is required for Nlrp3 inflammasome activation. Immunity. 2013;39:311–323.|||Stevens DA, et al. Parkin loss leads to PARIS-dependent declines in mitochondrial mass and respiration. Proc Natl Acad Sci USA. 2015;112:11696–11701.|||Tao L, et al. Exercise training protects against acute myocardial infarction via improving myocardial energy metabolism and mitochondrial biogenesis. Cell Physiol Biochem. 2015;37:162–175.|||Bouitbir J, et al. Opposite effects of statins on mitochondria of cardiac and skeletal muscles: a ‘mitohormesis’ mechanism involving reactive oxygen species and PGC-1. Eur Heart J. 2012;33:1397–1407.|||Yamamoto T, et al. Nicotinamide mononucleotide, an intermediate of NAD+ synthesis, protects the heart from ischemia and reperfusion. PLoS ONE. 2014;9:e98972.|||Ong SB, Hausenloy DJ. Mitochondrial dynamics as a therapeutic target for treating cardiac diseases. Handb Exp Pharmacol. 2016 http://dx.doi.org/10.1007/164_2016_7.|||Ong SB, et al. Inhibiting mitochondrial fission protects the heart against ischemia/reperfusion injury. Circulation. 2010;121:2012–2022.|||Gustafsson AB, Gottlieb RA. Bcl-2 family members and apoptosis, taken to heart. Am J Physiol Cell Physiol. 2007;292:C45–C51.|||Kloner RA. No-reflow phenomenon: maintaining vascular integrity. J Cardiovasc Pharmacol Ther. 2011;16:244–250.|||Reffelmann T, Kloner RA. The “no-reflow” phenomenon: basic science and clinical correlates. Heart. 2002;87:162–168.|||Rezkalla SH, Kloner RA. No-reflow phenomenon. Circulation. 2002;105:656–662.|||Kloner RA, Ganote CE, Jennings RB. The “no-reflow” phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974;54:1496–1508.|||Reffelmann T, Kloner RA. Microvascular reperfusion injury: rapid expansion of anatomic no reflow during reperfusion in the rabbit. Am J Physiol Heart Circ Physiol. 2002;283:H1099–H1107.|||Kloner RA, Alker KJ. The effect of streptokinase on intramyocardial hemorrhage, infarct size, and the no-reflow phenomenon during coronary reperfusion. Circulation. 1984;70:513–521.|||Zhao JL, Yang YJ, Cui CJ, You SJ, Gao RL. Pretreatment with simvastatin reduces myocardial no-reflow by opening mitochondrial KATP channel. Br J Pharmacol. 2006;149:243–249.|||Reffelmann T, Hale SL, Dow JS, Kloner RA. No-reflow phenomenon persists long-term after ischemia/reperfusion in the rat and predicts infarct expansion. Circulation. 2003;108:2911–2917.|||Ito H. Etiology and clinical implications of microvascular dysfunction in patients with acute myocardial infarction. Int Heart J. 2014;55:185–189.|||Rezkalla SH, Dharmashankar KC, Abdalrahman IB, Kloner RA. No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: incidence, outcome, and effect of pharmacologic therapy. J Interv Cardiol. 2010;23:429–436.|||Schwartz BG, Kloner RA. Coronary no reflow. J Mol Cell Cardiol. 2012;52:873–882.|||Judd RM, et al. Physiological basis of myocardial contrast enhancement in fast magnetic resonance images of 2-day-old reperfused canine infarcts. Circulation. 1995;92:1902–1910.|||Wu KC, et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation. 1998;97:765–772.|||Bolognese L, et al. Impact of microvascular dysfunction on left ventricular remodeling and long-term clinical outcome after primary coronary angioplasty for acute myocardial infarction. Circulation. 2004;109:1121–1126.|||Galiuto L, et al. The extent of microvascular damage during myocardial contrast echocardiography is superior to other known indexes of post-infarct reperfusion in predicting left ventricular remodeling: results of the multicenter AMICI study. J Am Coll Cardiol. 2008;51:552–559.|||White HD, et al. Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation. 1987;76:44–51.|||Ndrepepa G, et al. 5-year prognostic value of no-reflow phenomenon after percutaneous coronary intervention in patients with acute myocardial infarction. J Am Coll Cardiol. 2010;55:2383–2389.|||Niccoli G, Burzotta F, Galiuto L, Crea F. Myocardial no-reflow in humans. J Am Coll Cardiol. 2009;54:281–292.|||Hale SL, Herring MJ, Kloner RA. Delayed treatment with hypothermia protects against the no-reflow phenomenon despite failure to reduce infarct size. J Am Heart Assoc. 2013;2:e004234.|||Yang X, et al. Cardioprotection by mild hypothermia during ischemia involves preservation of ERK activity. Bas Res Cardiol. 2011;106:421–430.|||Ucar A, et al. The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nat Commun. 2012;3:1078.|||Jian X, et al. MiR-204 regulate cardiomyocyte autophagy induced by hypoxia-reoxygenation through LC3-II. Int J Cardiol. 2011;148:110–112.|||Mikhaylova O, et al. VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma. Cancer Cell. 2012;21:532–546.|||Xiao J, et al. MiR-204 regulates cardiomyocyte autophagy induced by ischemia-reperfusion through LC3-II. J Biomed Sci. 2011;18:35.|||Huang J, et al. miR-34a modulates angiotensin II-induced myocardial hypertrophy by direct inhibition of ATG9A expression and autophagic activity. PLoS ONE. 2014;9:e94382.|||Song L, et al. MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1. J Cell Mol Med. 2014;18:2266–2274.|||Pan W, et al. MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy. PLoS ONE. 2013;8:e53950.|||Li Q, et al. Overexpression of microRNA-99a attenuates heart remodelling and improves cardiac performance after myocardial infarction. J Cell Mol Med. 2014;18:919–928.